Cargando…

Validation of the International HIV Dementia Scale as a Screening Tool for HIV-Associated Neurocognitive Disorders in a German-Speaking HIV Outpatient Clinic

BACKGROUND: HIV-associated neurocognitive disorders (HAND) are widely present among people living with HIV. Especially its milder forms, asymptomatic neurocognitive impairment (ANI) and mild neurocognitive disorder (MND), remain highly prevalent worldwide. Diagnosing these conditions is subject to a...

Descripción completa

Detalles Bibliográficos
Autores principales: Marin-Webb, Victor, Jessen, Heiko, Kopp, Ute, Jessen, Arne B., Hahn, Katrin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5167352/
https://www.ncbi.nlm.nih.gov/pubmed/27992497
http://dx.doi.org/10.1371/journal.pone.0168225
_version_ 1782483164300574720
author Marin-Webb, Victor
Jessen, Heiko
Kopp, Ute
Jessen, Arne B.
Hahn, Katrin
author_facet Marin-Webb, Victor
Jessen, Heiko
Kopp, Ute
Jessen, Arne B.
Hahn, Katrin
author_sort Marin-Webb, Victor
collection PubMed
description BACKGROUND: HIV-associated neurocognitive disorders (HAND) are widely present among people living with HIV. Especially its milder forms, asymptomatic neurocognitive impairment (ANI) and mild neurocognitive disorder (MND), remain highly prevalent worldwide. Diagnosing these conditions is subject to a time and resource consuming neuropsychological assessment. Selecting patients at a higher risk of cognitive impairment by using a simple but effective screening tool helps to organise access to further neuropsychological diagnosis. The International HIV Dementia Scale (IHDS) has until now been a well-established screening tool in African and American countries, however these populations’ demographics defer significantly from ours, so using the same parameters could be ineffective. OBJECTIVES: To calculate the prevalence of this condition among people attending an HIV outpatient clinic in Berlin and to validate the use of the IHDS as a screening tool for HAND in a German-speaking population. METHODS: We screened 480 HIV-infected patients using the IHDS, 89% of them were on a stable antiretroviral treatment. Ninety of them completed a standardised neuropsychological battery of tests and a specific cognitive complaints questionnaire. The same procedure was applied to a control group of 30 HIV-negative participants. HAND diagnosis was established according to the Frascati criteria. RESULTS: The overall prevalence of HAND in our cohort was 43% (20% ANI, 17% MND and 6% HIV-associated dementia). The optimal cut-off on the IHDS for detecting HAND cases was set at 11 and achieved both a sensitivity and a specificity of 80%. When specifically screening for the more severe form of HAND, HIV-associated dementia, a cut-off value of 10 offered an increase in both sensitivity (94%) and specificity (86%). The Youden Index for diagnostic accuracy was 0.6 and 0.8, respectively. CONCLUSIONS: The prevalence of HAND was comparable to the reported by recent studies performed in countries with a similar economic development. The study confirms the IHDS to be a useful HAND screening tool in primary care settings and establishes new recommendations for its use in German-speaking countries.
format Online
Article
Text
id pubmed-5167352
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-51673522017-01-04 Validation of the International HIV Dementia Scale as a Screening Tool for HIV-Associated Neurocognitive Disorders in a German-Speaking HIV Outpatient Clinic Marin-Webb, Victor Jessen, Heiko Kopp, Ute Jessen, Arne B. Hahn, Katrin PLoS One Research Article BACKGROUND: HIV-associated neurocognitive disorders (HAND) are widely present among people living with HIV. Especially its milder forms, asymptomatic neurocognitive impairment (ANI) and mild neurocognitive disorder (MND), remain highly prevalent worldwide. Diagnosing these conditions is subject to a time and resource consuming neuropsychological assessment. Selecting patients at a higher risk of cognitive impairment by using a simple but effective screening tool helps to organise access to further neuropsychological diagnosis. The International HIV Dementia Scale (IHDS) has until now been a well-established screening tool in African and American countries, however these populations’ demographics defer significantly from ours, so using the same parameters could be ineffective. OBJECTIVES: To calculate the prevalence of this condition among people attending an HIV outpatient clinic in Berlin and to validate the use of the IHDS as a screening tool for HAND in a German-speaking population. METHODS: We screened 480 HIV-infected patients using the IHDS, 89% of them were on a stable antiretroviral treatment. Ninety of them completed a standardised neuropsychological battery of tests and a specific cognitive complaints questionnaire. The same procedure was applied to a control group of 30 HIV-negative participants. HAND diagnosis was established according to the Frascati criteria. RESULTS: The overall prevalence of HAND in our cohort was 43% (20% ANI, 17% MND and 6% HIV-associated dementia). The optimal cut-off on the IHDS for detecting HAND cases was set at 11 and achieved both a sensitivity and a specificity of 80%. When specifically screening for the more severe form of HAND, HIV-associated dementia, a cut-off value of 10 offered an increase in both sensitivity (94%) and specificity (86%). The Youden Index for diagnostic accuracy was 0.6 and 0.8, respectively. CONCLUSIONS: The prevalence of HAND was comparable to the reported by recent studies performed in countries with a similar economic development. The study confirms the IHDS to be a useful HAND screening tool in primary care settings and establishes new recommendations for its use in German-speaking countries. Public Library of Science 2016-12-19 /pmc/articles/PMC5167352/ /pubmed/27992497 http://dx.doi.org/10.1371/journal.pone.0168225 Text en © 2016 Marin-Webb et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Marin-Webb, Victor
Jessen, Heiko
Kopp, Ute
Jessen, Arne B.
Hahn, Katrin
Validation of the International HIV Dementia Scale as a Screening Tool for HIV-Associated Neurocognitive Disorders in a German-Speaking HIV Outpatient Clinic
title Validation of the International HIV Dementia Scale as a Screening Tool for HIV-Associated Neurocognitive Disorders in a German-Speaking HIV Outpatient Clinic
title_full Validation of the International HIV Dementia Scale as a Screening Tool for HIV-Associated Neurocognitive Disorders in a German-Speaking HIV Outpatient Clinic
title_fullStr Validation of the International HIV Dementia Scale as a Screening Tool for HIV-Associated Neurocognitive Disorders in a German-Speaking HIV Outpatient Clinic
title_full_unstemmed Validation of the International HIV Dementia Scale as a Screening Tool for HIV-Associated Neurocognitive Disorders in a German-Speaking HIV Outpatient Clinic
title_short Validation of the International HIV Dementia Scale as a Screening Tool for HIV-Associated Neurocognitive Disorders in a German-Speaking HIV Outpatient Clinic
title_sort validation of the international hiv dementia scale as a screening tool for hiv-associated neurocognitive disorders in a german-speaking hiv outpatient clinic
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5167352/
https://www.ncbi.nlm.nih.gov/pubmed/27992497
http://dx.doi.org/10.1371/journal.pone.0168225
work_keys_str_mv AT marinwebbvictor validationoftheinternationalhivdementiascaleasascreeningtoolforhivassociatedneurocognitivedisordersinagermanspeakinghivoutpatientclinic
AT jessenheiko validationoftheinternationalhivdementiascaleasascreeningtoolforhivassociatedneurocognitivedisordersinagermanspeakinghivoutpatientclinic
AT koppute validationoftheinternationalhivdementiascaleasascreeningtoolforhivassociatedneurocognitivedisordersinagermanspeakinghivoutpatientclinic
AT jessenarneb validationoftheinternationalhivdementiascaleasascreeningtoolforhivassociatedneurocognitivedisordersinagermanspeakinghivoutpatientclinic
AT hahnkatrin validationoftheinternationalhivdementiascaleasascreeningtoolforhivassociatedneurocognitivedisordersinagermanspeakinghivoutpatientclinic